

Differential effects of 7-OH-DPAT on the development of behavioral sensitization to apomorphine and cocaine

Bruce A. Mattingly*, Angela Caudill, Misti Abel

Department of Psychology, Morehead State University, 601 Ginger Hall, Morehead, KY 40351-1689, USA

Received 1 June 2000; received in revised form 18 October 2000; accepted 2 November 2000

Abstract

The primary objective of this study was to determine whether concurrent treatments with a low dose of the dopamine D₃-preferring receptor agonist 7-OH-DPAT would attenuate the development of behavioral sensitization to the indirect dopamine receptor agonist, cocaine, or the direct dopamine receptor agonist, apomorphine. In two experiments, male Wistar rats (250–350 g) were given seven daily injections of 7-OH-DPAT (0.05 mg/kg sc) or vehicle in combination with either cocaine (15 mg/kg ip), apomorphine (1.0 mg/kg sc), or vehicle. After the injections, the rats were tested for activity in photocell arenas for 40 min, and three measures of motor behavior (distance traveled, rearing, and stereotypy) were recorded at 10-min intervals. A total of 24 h after the last preexposure session, all rats were given a challenge injection of either cocaine (10.0 mg/kg ip, Experiment 1) or apomorphine (1.0 mg/kg sc, Experiment 2) and tested for activity. Major findings were as follows: (a) 7-OH-DPAT treatments alone suppressed all measures of locomotor activity and did not affect subsequent behavioral sensitivity to either cocaine or apomorphine; (b) cocaine treatments acutely increased all measures of activity, and repeated treatments produced behavioral sensitization to the horizontal locomotor-activating effects of cocaine; (c) apomorphine treatments alone increased horizontal activity and stereotypy but completely abolished rearing behavior; (d) like cocaine, repeated treatments with apomorphine induced behavioral sensitization; (e) concurrent treatments of 7-OH-DPAT with cocaine acutely attenuated cocaine-induced increases in motor behavior but enhanced the development of behavioral sensitization to cocaine; and (f) concurrent 7-OH-DPAT treatments did not significantly affect either the acute or chronic effects of apomorphine. It is evident from these results that concurrent treatment with 7-OH-DPAT does not block the development of behavioral sensitization to either cocaine or apomorphine. Moreover, the differential acute and chronic effects of 7-OH-DPAT on cocaine- and apomorphine-induced hyperactivity appear to be mediated by dopamine autoreceptor stimulation. © 2001 Elsevier Science Inc. All rights reserved.

Keywords: Behavioral sensitization; 7-OH-DPAT; Cocaine; Apomorphine; Locomotor activity; Dopamine D₃ receptors; Dopamine D₂ receptors; Autoreceptors

1. Introduction

It has been repeatedly suggested in recent years that the dopamine D₃ receptor may be an important target for the development of pharmacotherapies for the treatment of psychostimulant drug abuse (e.g., Caine and Koob, 1993; Caine et al., 1997; Khroyan et al., 1998; Shafer and Levant, 1998). Consistent with this suggestion, dopamine D₃ receptors appear to be preferentially located in limbic regions important for incentive motivation and reward (see Shafer and Levant, 1998 for review), and the number of binding sites for D₃ receptors are significantly elevated

in cocaine-overdosed victims (Staley and Mash, 1996). In addition, the dopamine D₃-preferring receptor agonist, 7-OH-DPAT, modulates cocaine self-administration in rats at doses that are not readily self-administered alone (Caine and Koob, 1993, 1995; Caine et al., 1999; Nader and Mach, 1996; Parsons et al., 1996), substitutes for cocaine, amphetamine, and apomorphine in drug discrimination tasks (Acri et al., 1995; Baker et al., 1998; Sanger et al., 1997), and attenuates the incentive motivational properties of amphetamine, cocaine, and morphine as measured by conditioned place preference (CPP) tests (DeFonseca et al., 1995; Khroyan et al., 1998, 1999). Based upon these and other findings, it has been suggested that 7-OH-DPAT maybe useful in the treatment of drug craving in recovering addicts (e.g., Caine and Koob, 1993; Caine et al., 1997).

* Corresponding author. Tel.: +1-606-783-2981; fax: +1-606-783-5077.

Like dopamine D₂ receptors, D₃ receptors appear to be located on both pre- and postsynaptic membranes (e.g., Aretha et al., 1995; Booth et al., 1994; Gilbert et al., 1995; Svensson et al., 1994b). Moreover, considerable evidence suggests that the D₃ presynaptic receptor functions as an autoreceptor (see Shafer and Levant, 1998 for review). For example, acute treatment with 7-OH-DPAT produces hypoactivity in rats (e.g., Mattingly et al., 1996; Svensson et al., 1994b), as well as a significant decrease in dopamine synthesis, release, and dopamine cell firing rates (e.g., Acri et al., 1995; Gilbert et al., 1995; Kreiss et al., 1995; Lejeune and Millan, 1995). Despite this evidence, however, it has been more recently reported that the dopamine D₃-preferring agonist, PD 128907, produces similar effects in models of autoreceptor function in wild-type and D₃ “knock-out” mice (Koeltzow et al., 1998). Based upon this result, it has been argued that D₃ receptors do not function as autoreceptors (Koeltzow et al., 1998). Consistent with this conclusion, decreases in locomotor activity have been reported following low doses of 7-OH-DPAT that do not affect dopamine synthesis or release (Mattingly et al., 1996; Svensson et al., 1994b). Based upon this latter finding, it has been suggested that dopamine D₃ postsynaptic receptors, unlike postsynaptic D₂ receptors, may be inhibitory with respect to locomotor behavior (Svensson et al., 1994a,b).

Many of the behavioral effects of psychostimulant drugs, including cocaine and amphetamine, increase with repeated drug exposure (Kalivas and Stewart, 1993; Robinson and Becker, 1986; Stewart and Badiani, 1993). This phenomenon, termed behavioral sensitization, has now been extensively documented for both the locomotor-activating and rewarding effects of psychostimulant drugs (e.g., Pierre and Vezina, 1997; Robinson and Berridge, 1993; Shippenberg and Heidbreder, 1995), and has been proposed as an animal model for the development and persistence of drug craving (Kalivas et al., 1998; Robinson and Berridge, 1993). Previous research indicates that nearly all dopamine agonists, including 7-OH-DPAT, produce behavioral sensitization with repeated treatments (e.g., Mattingly et al., 1996). However, although high doses of 7-OH-DPAT result in the development of behavioral sensitization with repeated treatment, repeated treatments with low doses of 7-OH-DPAT, presumably selective for D₃ receptors (Levant et al., 1996), inhibit locomotor activity and do not induce behavioral sensitization (Mattingly et al., 1996).

The purpose of the current study, therefore, was to determine whether concurrent treatments with a low dose 7-OH-DPAT would attenuate the development of behavioral sensitization. Consequently, in Experiment 1, rats were treated daily with a low dose of 7-OH-DPAT combined with either cocaine or vehicle and tested for locomotor activity. After this pretreatment, all rats were tested for activity following a challenge dose of cocaine. Experiment 2 was the same as Experiment 1, except that the direct dopamine agonist, apomorphine, was used in place of cocaine. Although the development of behavioral sensitiza-

tion to both cocaine and apomorphine is presumed to result from repeated dopamine receptor stimulation (e.g., Henry et al., 1989; Henry and White, 1995; Mattingly et al., 1991), the two drugs differ in mechanism of action. Cocaine promotes an increase in extracellular dopamine by blocking the dopamine transporter, whereas, apomorphine is a relatively nonselective direct dopamine receptor agonist. Thus, concurrent 7-OH-DPAT treatments may differentially affect the development of sensitization to these two drugs (cf. Khroyan et al., 1999).

2. Materials and methods

2.1. Subjects

In each experiment, 32 male Wistar albino rats (Harlan Sprague–Dawley; Indianapolis, IN) weighing between 250 and 350 g served as subjects. The rats were housed in the colony room for at least 1 week prior to behavioral testing. All rats were housed individually in hanging wire-mesh cages in a colony room with a 12-h light–dark cycle and food and water available continuously. All behavioral testing was conducted during the light phase of the cycle.

2.2. Apparatus

Activity measures were taken in four acrylic open-field chambers (Med-Associates Model OFA-163) located individually in sound-attenuated experimental cubicles. These chambers were equipped with a 16 × 16 array of photocell beams and detectors 2.5 cm above the floor and single array of 16 photocell beams and detectors 10 cm above the floor. In each chamber, a clear acrylic cylinder (41 cm in diameter) was placed inside the outer square chamber. The photocell banks were connected to a microcomputer in an adjoining room. Using Med-Associates software, three measures of activity were recorded at 10-min intervals: distance traveled (cm), number of rears, and stereotypy (small movements).

2.3. Drugs

Apomorphine hydrobromide (Sigma), cocaine hydrochloride (NIDA), and (±)-7-hydroxy-dipropylaminotetralin hydrobromide (7-OH-DPAT; Research Biochemicals) were dissolved in distilled H₂O and injected in a volume of 1.0 ml/kg. Doses of each drug were calculated based upon the salt form of the drug. Vehicle injections were given using the same route and volume as the corresponding drug injection. Doses of apomorphine (1.0 mg/kg) and cocaine (15 mg/kg) known to reliably induce behavioral sensitization were chosen based upon previous research in our laboratory (Mattingly et al., 1988a,b, 1991, 1994). The dose of 7-OH-DPAT (0.05 mg/kg) was chosen, because it acutely decreases activity, does not induce behavioral sensitization with repeated treatment, and has been suggested to be




Fig. 1. Mean \pm S.E.M. distance traveled across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 15.0 mg/kg cocaine (COC).

selective for dopamine D₃ receptors (Gainetdinov et al., 1996; Levant et al., 1996; Mattingly et al., 1996).

2.4. Design and procedure

At the beginning of Experiment 1, 32 rats were randomly assigned in equal numbers to one of four treatment groups comprising the two (7-OH-DPAT dose: 0 or 0.05 mg/kg) \times two (cocaine dose: 0 or 15.0 mg/kg) factorial design. The design of Experiment 2 was the same as Experiment 1, except that apomorphine (0 or 1.0 mg/kg) was used in place of cocaine. In Experiment 1, prior to each of the first seven sessions (training phase), the rats were first injected subcutaneously (sc) with either vehicle or 7-OH-DPAT and then immediately injected intraperitoneally (ip) with either vehicle or cocaine. A total of 5 min following the second injection, each rat was placed into the activity chamber. On Session 8 (sensitization test), all rats received a vehicle injection followed immediately by an injection of cocaine (10.0 mg/kg). The same procedure was followed in Experiment 2, except that 7-OH-DPAT and apomorphine were administered subcutaneously in a cocktail during the training phase, and a single injection of apomorphine (1.0 mg/kg) was administered on the sensitization test. In all phases of the experiments, the rats were returned to their homecage after the injections prior to activity testing. All activity test sessions were 40 min in duration and separated by 24-h drug-free intervals. This experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee at Morehead State University.

2.5. Data analysis

Significant differences among the groups in mean activity counts during the training phase (Sessions 1–7) were determined with mixed four-factor analyses of variance (ANOVA) using drug treatment conditions as between

factors, and test session and blocks of 10 min within each session as repeated measures. Significant interactions were analyzed with additional ANOVAs performed on individual session and/or block data followed by Newman–Keuls post-hoc tests. Mean activity counts of the groups on the sensitization test (Session 11) were analyzed using mixed three-factor ANOVAs.

3. Results

3.1. Experiment 1: 7-OH-DPAT and cocaine

3.1.1. Training sessions — distance traveled

The mean distance traveled by the four groups across the four 10-min time blocks on Sessions 1, 4, and 7 are displayed in Fig. 1. As may be seen in Fig. 1, cocaine produced a progressive increase in horizontal locomotor activity with repeated administration [cocaine effect, $F(1,28)=227.92$, $P<.0001$, and Cocaine \times Session interaction, $F(6,168)=7.05$, $P<.0001$]. In contrast, 7-OH-DPAT suppressed activity in both vehicle- and cocaine-treated rats on the first 10-min block of each session [7-OH-DPAT \times Block, $F(3,84)=46.59$, $P<.0001$]. However, although the 7-OH-DPAT-induced suppression of activity did not significantly change across sessions in vehicle-treated rats, the activity of rats injected with both 7-OH-DPAT and cocaine significantly increased across sessions [7-OH-DPAT \times Cocaine \times Block interaction, $F(3,84)=5.55$, $P<.002$, and 7-OH-DPAT \times Cocaine \times Session \times Block interaction, $F(18,504)=1.96$, $P=.0105$]. Thus, while concurrent 7-OH-DPAT treatments produced an initial inhibition of cocaine-induced activity across sessions, it did not prevent the development of behavioral sensitization.

3.1.2. Sensitization test — distance traveled

The results of the cocaine challenge on horizontal locomotor activity are shown in Fig. 2. As may be seen the left




Fig. 2. Mean \pm S.E.M. distance traveled after a cocaine challenge injection (10.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or cocaine (15.0 mg/kg, COC). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

panel, rats previously treated with cocaine with or without 7-OH-DPAT were significantly more active after the cocaine challenge injection than rats previously treated with either 7-OH-DPAT alone or vehicle [cocaine effect, $F(1,28)=17.74$, $P=.0002$]. However, as may be seen in the right panel of Fig. 2, this effect varied across blocks [Cocaine \times Block interaction, $F(3,84)=16.59$, $P=.0001$; 7-OH-DPAT \times Cocaine \times Block interaction, $F(3,84)=3.60$, $P=.0169$]. Indeed, subsequent analysis of the triple interaction with a Newman–Keuls post-hoc test indicated that cocaine-pretreated rats were significantly more active than the vehicle control rats only on Blocks 1 and 2 [P 's $<.05$]. In contrast, the rats pretreated with 7-OH-DPAT alone did not differ significantly from the vehicle control rats on any block [P 's $>.05$]. More important, the rats previously treated with both 7-OH-DPAT and cocaine were significantly more active than the other three groups on Blocks 2, 3, and 4 [P 's $<.05$]. Thus, concurrent treatments with 7-OH-DPAT and cocaine during the training sessions appeared to prolong the effectiveness of the cocaine challenge treatment.

3.1.3. Training sessions — rears

The effects of 7-OH-DPAT and cocaine on rearing are shown in Fig. 3. As may be seen, cocaine significantly stimulated rearing behavior compared to vehicle control rats [cocaine effect, $F(1,28)=57.77$, $P<.0001$]. However, this cocaine-induced increase in rearing did not significantly change across sessions. In contrast, 7-OH-DPAT treatments significantly suppressed rearing across all sessions [7-OH-DPAT effect, $F(1,28)=10.74$, $P=.0028$], with the greatest suppression occurring on the early blocks of each session [7-OH-DPAT \times Block interaction, $F(3,84)=67.00$, $P<.0001$]. Concurrent 7-OH-DPAT treatments also significantly inhibited the cocaine-induced increase in rearing across sessions, particularly on the early blocks of each session [7-OH-DPAT \times Cocaine \times Block, $F(3,84)=7.90$, $P<.0001$].




Fig. 3. Mean \pm S.E.M. rears across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 15.0 mg/kg cocaine (COC).




Fig. 4. Mean \pm S.E.M. rears after a cocaine challenge injection (10.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or cocaine (15.0 mg/kg, COC). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

3.1.4. Sensitization test — rears

The results of the cocaine challenge treatment on rearing are shown in Fig. 4. As may be seen in the left panel, neither 7-OH-DPAT nor cocaine pretreatments significantly affected the overall number of rears after the cocaine challenge injection. However, as shown in the right panel, these treatments did appear to increase cocaine-induced rearing on the first block of this test session [7-OH-DPAT \times Cocaine \times Block interaction, $F(3,84)=2.89$, $P<.05$]. Analysis of this latter interaction indicated that the two groups of 7-OH-DPAT-pretreated rats displayed significantly more rearing than the vehicle-pretreated rats on Block 1 of this session [P 's $<.05$]. However, the rearing behavior of the two 7-OH-DPAT groups did not significantly differ from that of the cocaine-pretreated rats [P 's $>.05$]. No significant differences in rearing were observed among the groups on Blocks 2, 3, and 4 [P 's $>.05$]. Thus, consistent with the results of the training sessions, repeated cocaine treatments did not result in the development of sensitization to rearing. Although 7-OH-DPAT treatments suppressed rearing during the training sessions, these treatments did not decrease subsequent sensitivity to cocaine using rearing as a behavioral measure.

3.1.5. Training sessions — stereotypy score

The effects of repeated 7-OH-DPAT and cocaine treatments on stereotypic movements are shown in Fig. 5. It should be noted that this measure of stereotypy can not distinguish among various normal head and limb movements and traditional measures of drug-induced stereotypy, such as sniffing, licking, head-bobbing, etc. Thus, it primarily measures drug-induced changes in the total number of small movements per unit time. As may be seen, cocaine significantly stimulated such movements compared to vehicle control rats across all sessions and blocks [cocaine effect, $F(1,28)=322.85$, $P<.0001$], but this increase did not change across sessions. 7-OH-DPAT significantly decreased stereotypy scores, but this inhibition decreased across days as the stereotypy scores of the vehicle control




Fig. 5. Mean \pm S.E.M. stereotypy counts across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 15.0 mg/kg cocaine (COC).

rats significantly decreased, particularly on the latter blocks of each session [7-OH-DPAT \times Session interaction, $F(6,168) = 5.35$, $P < .0001$; 7-OH-DPAT \times Block interaction, $F(3,84) = 62.59$, $P < .0001$]. Although 7-OH-DPAT suppressed stereotypy scores overall for vehicle-treated rats, the effect of 7-OH-DPAT on cocaine-induced stereotypy scores appeared to change across blocks. Indeed, a separate analysis of Session 1 indicated that the rats treated with 7-OH-DPAT and cocaine did not differ from rats treated with only cocaine on any block (P 's $> .05$). In contrast, on Session 7, rats treated with the combination of cocaine and 7-OH-DPAT displayed significantly higher stereotypy scores on Blocks 2, 3, and 4 than rats treated with cocaine alone (P 's $< .05$). Thus, repeated 7-OH-DPAT treatments with cocaine enhanced the stimulating effects of cocaine on stereotypic movements.

3.1.6. Sensitization test — stereotypy scores

The results of the cocaine challenge injection on stereotypy counts are shown in Fig. 6. Consistent with the training




Fig. 6. Mean \pm S.E.M. stereotypy counts after a cocaine challenge injection (10.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or cocaine (15.0 mg/kg, COC). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

session, repeated cocaine treatments did not produce behavioral sensitization to cocaine-induced stereotypy. Although concurrent 7-OH-DPAT treatments with cocaine appeared to increase cocaine-induced stereotypy compared to vehicle treatments, this increase was not significant [7-OH-DPAT \times Cocaine interaction, $F(1,28) = 2.87$, $P > .05$; 7-OH-DPAT \times Cocaine \times Block, $F(3,84) = 0.77$]. Thus, although concurrent 7-OH-DPAT treatments increased cocaine-induced stereotypy scores during the training sessions, this pretreatment did not significantly affect subsequent sensitivity to cocaine-induced stereotypy.

3.2. Experiment 2: 7-OH-DPAT and apomorphine

3.2.1. Training sessions — distance traveled

The mean distance traveled by the four groups across the four 10-min blocks of Sessions 1, 4, and 7 are shown in Fig. 7. As may be seen in Fig. 7, apomorphine produced a progressively greater increase in activity across sessions [apomorphine effect, $F(1,28) = 66.54$, $P < .0001$; Apomorphine \times Session interaction, $F(6,168) = 30.16$, $P < .0001$]. Consistent with Experiment 1, 7-OH-DPAT treatments produced a significant inhibition of activity compared to vehicle-treated rats on the first 10-min block of each session [7-OH-DPAT \times Block interaction, $F(3,84) = 4.26$, $P = .0075$]. However, in contrast to Experiment 1, 7-OH-DPAT treatments did not significantly attenuate the stimulating effects of apomorphine. Indeed, a separate analysis of Session 7 revealed a significant main effect of apomorphine treatment [$F(1,28) = 79.22$, $P < .0001$] and a significant Apomorphine \times Block interaction [$F(3,84) = 28.16$, $P < .0001$]. However, none of the effects involving 7-OH-DPAT as a factor were significant. Thus, concurrent treatments with 7-OH-DPAT did not affect either the locomotor-stimulating effects of apomorphine or the development of behavioral sensitization to apomorphine.




Fig. 7. Mean \pm S.E.M. distance traveled across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 1.0 mg/kg apomorphine (APO).




Fig. 8. Mean ± S.E.M. distance traveled after an apomorphine challenge injection (1.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or apomorphine (1.0 mg/kg, APO). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

3.2.2. Sensitization test — distance traveled

The results of the apomorphine challenge test on distance traveled are shown in Fig. 8. As may be seen in the left panel of Fig. 8, rats previously treated with apomorphine with or without 7-OH-DPAT were significantly and equally more active after the apomorphine challenge injection than rats previously treated with only vehicle [apomorphine effect, $F(1,28)=4.22, P<.0001$]. As shown in the right panel, this sensitization effect was greatest on the first block of the test session [block effect, $F(3,84)=67.67, P<.0001$, and Apomorphine × Block interaction, $F(3,84)=25.83, P<.0001$]. Prior treatment with 7-OH-DPAT did not significantly affect subsequent sensitivity to apomorphine for rats also pretreated with either vehicle or apomorphine. Thus, consistent with the results of the training sessions, concurrent treatments with 7-OH-DPAT did not affect the development of behavioral sensitization to apomorphine using horizontal locomotor activity as a behavioral measure.

APOMORPHINE CHALLENGE TEST




Fig. 10. Mean ± S.E.M. rears after an apomorphine challenge injection (1.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or apomorphine (1.0 mg/kg, APO). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

3.2.3. Training sessions — rears

The effect of repeated 7-OH-DPAT and/or apomorphine treatments on rearing behavior is shown in Fig. 9. In contrast to the stimulating effects of cocaine observed in Experiment 1, apomorphine treatments almost completely abolished rearing behavior across for both sessions and blocks [apomorphine effect, $F(1,28)=99.89, P<.0001$]. Consistent with Experiment 1, treatment with 7-OH-DPAT also decreased rearing compared to vehicle rats, but this 7-OH-DPAT-induced inhibition of rearing decreased across sessions and block [7-OH-DPAT × Block interaction, $F(3,84)=32.97, P<.0001$; 7-OH-DPAT × Session interaction, $F(6,168)=4.79, P<.001$]. Although probably due a floor effect, 7-OH-DPAT did not decrease rearing in apomorphine-treated rats [7-OH-DPAT × Apomorphine × Block interaction, $F(3,84)=33.47, P<.0001$, and 7-OH-DPAT × Apomorphine × Session interaction, $F(6,164)=4.79, P<.001$].




Fig. 9. Mean ± S.E.M. rears across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 1.0 mg/kg apomorphine (APO).




Fig. 11. Mean ± S.E.M. stereotypy counts across blocks of 10 min on Sessions 1, 4, and 7 for rats treated before each session with either vehicle (VEH) or 0.05 mg/kg 7-OH-DPAT (DPAT) and either vehicle or 15.0 mg/kg apomorphine (APO).

3.2.4. Sensitization test — rears

The results of the apomorphine challenge injection on rearing are shown in Fig. 10. As may be seen, the apomorphine challenge injection greatly suppressed rearing behavior in all pretreatment groups. Consequently, none of the effects involving either apomorphine or 7-OH-DPAT as a factor were significant.

3.2.5. Training sessions — stereotypy counts

The effects of repeated 7-OH-DPAT and apomorphine treatments on stereotypic counts on Sessions 1, 4, and 7 are displayed in Fig. 11. As may be seen, apomorphine treatments significantly increased stereotypy counts [apomorphine effect, $F(1,28)=229.22$, $P<.0001$]. Although this apomorphine-induced stimulation of stereotypy appeared to decrease across sessions, particularly on Block 1, neither the Apomorphine \times Session interaction nor the Apomorphine \times Session \times Block interaction approached significance. Consistent with Experiment 1, 7-OH-DPAT treatments significantly decreased stereotypy on the first session compared to vehicle rats, but this inhibition decreased across both sessions and blocks [7-OH-DPAT \times Session interaction, $F(6,168)=8.64$, $P<.0001$, and 7-OH-DPAT \times Block interaction, $F(3,84)=12.91$, $P<.0001$]. However, concurrent 7-OH-DPAT treatments did not significantly affect stereotypy counts in apomorphine-treated rats on any block [7-OH-DPAT \times Apomorphine \times Block interaction, $F(3,84)=13.04$, $P<.0001$]. These findings contrast with those from Experiment 1 that indicated that repeated 7-OH-DPAT treatments with cocaine significantly increased stereotypy counts compared to cocaine alone.

3.2.6. Sensitization test — stereotypy counts

The results of the apomorphine challenge test are shown in Fig. 12. Overall, as shown in the left panel, the various pretreatment combinations did not significantly affect apomorphine-induced stereotypy counts. However, as shown in the right panel, prior treatments with apomorphine with or

without 7-OH-DPAT did attenuate apomorphine-induced stereotypy counts on the first block of this test session [Apomorphine \times Block interaction, $F(3,84)=13.75$, $P<.0001$]. This finding is consistent with the tendency observed during the training sessions of declining stereotypy counts with repeated apomorphine treatments. This finding suggests that the stereotypy-inducing effects of apomorphine may undergo some tolerance with repeated apomorphine administration. 7-OH-DPAT treatments, however, did not influence this effect.

4. Discussion

Consistent with previous research, the low dose of 7-OH-DPAT used in the present study significantly suppressed both horizontal (distance traveled) and vertical (rearing) activity, as well as stereotypic small movements (Geter-Douglas et al., 1997; Mattingly et al., 1996). Furthermore, repeated treatments with 7-OH-DPAT alone did not induce behavioral sensitization and did not increase subsequent behavioral sensitivity to either apomorphine or cocaine (Mattingly et al., 1996). In contrast, cocaine acutely stimulated all measures of motor behavior and resulted in behavioral sensitization to the horizontal locomotor-activating effects of cocaine with repeated treatment. Like cocaine, apomorphine stimulated horizontal locomotion and stereotypy, and produced behavioral sensitization with repeated treatment (Mattingly et al., 1988a,b). However, unlike cocaine, apomorphine nearly completely abolished rearing behavior. The differential effect of apomorphine, cocaine, and 7-OH-DPAT on rearing behavior suggests that cocaine-induced increases in rearing may not be mediated by dopaminergic receptor stimulation. Indeed, dopamine receptor stimulation alone appears to directly inhibit this behavior.

When combined with cocaine, 7-OH-DPAT significantly attenuated cocaine-induced increases in horizontal locomotion and rearing. Although 7-OH-DPAT initially suppressed cocaine-induced increases in stereotypy, concurrent 7-OH-DPAT treatments produced an enhancement of cocaine-induced stereotypy with repeated treatments (cf. Fig. 11). Consistent with these findings, the D_3 -preferring receptor agonists, PD128907 and quinpirole, have been reported to attenuate the locomotor-activating effects of amphetamine (DeBoer et al., 1997; Furnidge et al., 1991), and the D_3 -preferring receptor antagonist, U99194A, has been reported to enhance the stimulating effects of amphetamine (Waters et al., 1993). The effects of these dopamine D_3 -preferring ligands on amphetamine-induced hyperactivity have been attributed to a preferential effect on dopamine autoreceptors (e.g., Furnidge et al., 1991). It has been assumed, for example, that concurrent stimulation of dopamine autoreceptors may attenuate amphetamine-induced hyperactivity by reducing the stimulant-induced increase in extracellular dopamine (e.g., Furnidge et al., 1991). However, as noted previously, it has also been argued that the locomotor




Fig. 12. Mean \pm S.E.M. stereotypy counts after a cocaine challenge injection (10.0 mg/kg) for rats previously treated subchronically with either vehicle (VEH) or 7-OH-DPAT (0.05 mg/kg, DPAT) and either vehicle or apomorphine (1.0 mg/kg, APO). The left panel represents the total session activity, and the right panel presents the same data as a function of four 10-min blocks within the session.

suppressive effects of D₃-preferring agonists are mediated exclusively by stimulation of postsynaptic D₃ receptors, which unlike D₁- and D₂-type postsynaptic receptors, are inhibitory with respect to locomotor activity (Svensson et al., 1994a,b; Waters et al.). Either of these mechanisms could account for the inhibitory effect of 7-OH-DPAT on acute cocaine-induced hyperactivity in the present study.

In contrast to the inhibitory effect of 7-OH-DPAT on cocaine-induced hyperactivity, concurrent 7-OH-DPAT treatments did not significantly affect apomorphine-induced changes in horizontal locomotion, stereotypy, or rearing. This differential effect of 7-OH-DPAT treatments on cocaine- and apomorphine-induced hyperactivity may be related to their different mechanisms of action. As noted previously, unlike cocaine, high doses of apomorphine are thought to increase locomotor activity by directly increasing stimulation of dopamine D₁- and D₂-type postsynaptic receptors independent of changes in synaptic dopamine levels. If so, then an autoreceptor-mediated reduction in dopamine release resulting from 7-OH-DPAT treatments may not be expected to affect apomorphine-induced increases in postsynaptic receptor stimulation (Khroyan et al., 1999), and therefore, locomotor activity. On the other hand, it has been hypothesized that concurrent 7-OH-DPAT treatments may suppress various behavioral effects of apomorphine by increasing the ratio of postsynaptic D₃ receptor stimulation to D₁ and/or D₂ receptor stimulation (Khroyan et al., 1999). Although 7-OH-DPAT should have increased D₃ postsynaptic receptor stimulation in the current study, this did not reduce the locomotor-activating effects of apomorphine. Thus, taken together, the suppressive effect of 7-OH-DPAT on cocaine-induced but not apomorphine-induced hyperactivity appears more consistent with increased autoreceptor stimulation rather than postsynaptic D₃ receptor stimulation. However, additional neurochemical data are clearly needed to help clarify these findings. For example, whether systemic treatments with low doses of 7-OH-DPAT actually reduce cocaine-induced increases in extracellular dopamine has apparently not been determined.

It should be noted that these findings contrast with those of a previous study (Khroyan et al., 1999), which reported some different effects of 7-OH-DPAT on apomorphine- and cocaine-induced activity and stereotypy. Although the exact reasons for this discrepancy are not clear, there were a number of methodological differences between the studies. For example, in the previous study (Khroyan et al., 1999), concurrent 7-OH-DPAT treatments did not attenuate cocaine-induced increases in horizontal locomotor activity. However, in contrast to the present study, a higher dose of 7-OH-DPAT was administered intraperitoneally with cocaine that did not suppress horizontal locomotor activity when administered alone (Khroyan et al., 1999). Moreover, in the current study, 7-OH-DPAT had its greatest effect on cocaine-induced activity within the first 10-min block. In the previous study, only

total activity over a 40-min period was reported (Khroyan et al., 1999). Any of these, as well as other differences between the two studies, may be responsible for the discrepant findings.

As discussed previously, concurrent treatments with low doses of 7-OH-DPAT have been reported to attenuate the development of CPP to cocaine, amphetamine, and morphine (DeFonseca et al., 1995; Khroyan et al., 1998, 1999). In contrast, concurrent 7-OH-DPAT treatments do not attenuate the development of CPP to apomorphine (Khroyan et al., 1999). These findings seem congruent with the differential acute effects of 7-OH-DPAT on cocaine- and apomorphine-induced horizontal locomotor activity in the present study. That is, 7-OH-DPAT attenuated cocaine-induced but not apomorphine-induced increases in activity. Consistent with the current study, the 7-OH-DPAT attenuation of CPP was attributed to the stimulation of dopamine autoreceptors by 7-OH-DPAT, resulting in an attenuation of drug-induced increases in the synaptic levels of dopamine (Khroyan et al., 1999). Taken together with the current results, these findings suggest that the locomotor-activating and rewarding effects of cocaine and apomorphine may be mediated by similar mechanisms.

Although concurrent treatments with 7-OH-DPAT attenuated the cocaine-induced increase in horizontal activity during the pretreatment sessions, this concurrent treatment did not attenuate the development of behavioral sensitization to cocaine. Indeed, rats previously treated with both 7-OH-DPAT and cocaine displayed a more prolonged increase in horizontal locomotor activity after the cocaine challenge injection than rats previously treated with only cocaine. Thus, if anything, 7-OH-DPAT enhanced the development of behavioral sensitization to cocaine. In contrast, 7-OH-DPAT did not affect the development of behavioral sensitization to apomorphine.

At present, the mechanism responsible for this 7-OH-DPAT-induced enhancement in the development of behavioral sensitization to cocaine is not clear. One possible explanation is that concurrent 7-OH-DPAT treatments with cocaine enhanced the development of autoreceptor subsensitivity. Autoreceptor subsensitivity has been proposed as an initial event in the cellular cascade associated with the development of behavioral sensitization to psychomotor stimulants (see Henry et al., 1989; Henry and White, 1995; Wolf et al., 1993). According to this hypothesis, sensitization may involve at least two cellular alterations in the mesocorticolimbic dopamine system: an initial and transient decrease in the sensitivity of D₂-type autoreceptors followed by a long-lasting increase in the sensitivity of D₁-type postsynaptic receptors. Thus, the 7-OH-DPAT enhancement of cocaine sensitization may be due to a greater decrease in autoreceptor sensitivity. In a previous study (Mattingly et al., 1996), however, basal dopamine synthesis was not affected by repeated 7-OH-DPAT treatments, suggesting that synthesis-modulating autoreceptors do not become subsensitive with repeated 7-OH-DPAT

treatments (Mattingly et al., 1996). Of course, the regulation of synthesis-modulating autoreceptors may differ from impulse- or release-modulating autoreceptors (Rowlett et al., 1997), and acute 7-OH-DPAT treatments have been reported to have a greater effect on release-modulating than synthesis-modulating autoreceptors (Gainetdinov et al., 1996). Although repeated apomorphine treatments also result in the development of autoreceptor subsensitivity (Rowlett et al., 1991, 1997), as noted before, the expression of sensitization to apomorphine may be less affected by changes in dopamine release than indirect dopamine agonists, such as cocaine.

In conclusion, the current findings indicate that concurrent treatment with the putative dopamine D₃-preferring receptor agonist 7-OH-DPAT has differential effects on the acute and chronic effects of the indirect dopamine agonist, cocaine, and the direct dopamine agonist, apomorphine. Although 7-OH-DPAT acutely attenuated the locomotor-activating effects of cocaine, concurrent treatments with 7-OH-DPAT and cocaine enhanced the development of behavioral sensitization. In contrast, concurrent treatments with 7-OH-DPAT did not affect either the acute motor effects of apomorphine or the development of behavioral sensitization to apomorphine. Although more research is needed, the differential effects 7-OH-DPAT on the acute and chronic effects of cocaine and apomorphine appear more consistent with an explanation based upon dopamine autoreceptor stimulation than postsynaptic D₃ receptor stimulation. Although the dose of 7-OH-DPAT used in the present study is thought to be selective for dopamine D₃ receptors (Gainetdinov et al., 1996; Levant et al., 1996), whether or not the current findings with 7-OH-DPAT are mediated exclusively by D₃ receptor stimulation is not clear. As noted previously, based upon research with D₃ “knock-out” mice, it has been suggested that D₃ receptors do not function as autoreceptors (Koeltzow et al., 1998). Although evidence from these genetically altered mice must be interpreted with caution due to potential developmental compensations (Shafer and Levant, 1998), if accurate, the current findings with 7-OH-DPAT may involve dopamine D₂ rather than D₃ autoreceptors. Finally, to the extent that behavioral sensitization is a valid model of drug craving, the current results suggests that concurrent treatments with 7-OH-DPAT may enhance rather than attenuate the development of craving. On the other hand, since 7-OH-DPAT treatment alone did not increase subsequent behavioral sensitivity to either cocaine or apomorphine, it is possible that 7-OH-DPAT treatments during drug withdrawal will not maintain or enhance drug craving.

Acknowledgments

This research was supported by USPHS grant DA 09687 to B.A.M. The authors are grateful to Brandon Harding,

Liubov Leontieva, and Nadine Melahn for their assistance in behavioral testing.

References

- Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikstrom H, Katz J, Witkin JM. Assessment of cocaine-like discriminative stimulus effects of dopamine D₃ receptor ligands. *Eur J Pharmacol* 1995;281:7–9.
- Aretha CW, Sinha A, Galloway MP. Dopamine D₃-preferring ligands act at synthesis modulating autoreceptors. *J Pharmacol Exp Ther* 1995;274:609–13.
- Baker LE, Svensson KA, Garner KJ, Goodwin AK. The dopamine D₃ receptor antagonist PNU-99194A fails to block (+)-7-OH-DPAT substitution for D-amphetamine or cocaine. *Eur J Pharmacol* 1998;358:101–9.
- Booth RG, Baldessarini RJ, Marsh E, Owens CE. Actions of (+/-)-7-hydroxy-*N,N*-dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of the rat brain. *Brain Res* 1994;662:283–8.
- Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. *Science* 1993;260:1814–6.
- Caine SB, Koob GF. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose–effect function to the left under different schedules in the rat. *Behav Pharmacol* 1995;6:333–47.
- Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz J-C, Sokoloff P. D₃ receptor in vitro predicts decreased cocaine self-administration in rats. *NeuroReport* 1997;8:2372–7.
- Caine SB, Negus SS, Mello NK, Bergman J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. *J Pharmacol Exp Ther* 1999;291:353–60.
- DeBoer P, Enrico P, Wright J, Wise LD, Timmerman W, Moor E, Dijkstra D, Wikstryom HV, Westerink BH. Characterization of the effect of dopamine D₃ receptor stimulation on locomotion and striatal dopamine levels. *Brain Res* 1997;758:83–91.
- DeFonseca RF, Rubio P, Martyin-Calderyon JL, Caine SB, Koob GF, Navarro M. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. *Eur J Pharmacol* 1995;274:47–53.
- Furmidge L, Tong Z-Y, Clark D. Effects of low, autoreceptor selective doses of dopamine agonists on the discriminative cue and locomotor hyperactivity produced by D-amphetamine. *J Neural Transm* 1991;86:61–70.
- Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. In vivo evidence for preferential role of dopamine D₃ receptors in the presynaptic regulation of dopamine release but not synthesis. *Eur J Pharmacol* 1996;308:261–9.
- Geter-Douglas B, Katz JL, Alling K, Acri JB, Witkin JM. Characterization of unconditioned behavioral effects of dopamine D₃/D₂ receptor agonists. *J Pharmacol Exp Ther* 1997;283:7–15.
- Gilbert DB, Millar J, Cooper SJ. The putative dopamine D₃ agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. *Brain Res* 1995;681:1–7.
- Henry DJ, White FJ. The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons. *J Neurosci* 1995;15:6287–99.
- Henry DJ, Greene MA, White FJ. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: repeated administration. *J Pharmacol Exp Ther* 1989;258:833–9.
- Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. *Brain Res Rev* 1993;16:223–44.
- Kalivas PW, Pierce RC, Cornish J, Sorg BA. A role for sensitization in craving and relapse in cocaine addiction. *J Psychopharmacol* 1998;12:49–53.

- Khroyan TV, Baker DA, Fuchs RA, Manders N, Neisewander JL. Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference. *Psychopharmacology* 1998;139:332–41.
- Khroyan TV, Fuchs RA, Beck AM, Groff RS, Neisewander JL. Behavioral interactions produced by co-administration of 7-OH-DPAT with cocaine and apomorphine. *Psychopharmacology* 1999;142:383–92.
- Koeltzow TE, Xu M, Cooper DC, Hu X-T, Tonegawa S, Wolf ME, White FJ. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D₃ receptor mutant mice. *J Neurosci* 1998;18:2231–8.
- Kreiss DS, Bergstrom DA, Gonzales AM, Huang KX, Sibley DR, Walters JR. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D₃ receptor binding affinities. *Eur J Pharmacol* 1995;277:209–14.
- Lejeune F, Millan MJ. Activation of dopamine D₃ autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. *Eur J Pharmacol* 1995;275:7–9.
- Levant B, Bancroft GN, Selkirk CM. In vivo occupancy of D₂ dopamine receptors by 7-OH-DPAT. *Synapse* 1996;24:60–4.
- Mattingly BA, Gotsick JE, Marin C. Locomotor activity and stereotypy in rats following repeated apomorphine treatments at 1-, 3-, or 7-day intervals. *Pharmacol Biochem Behav* 1988;31:871–5.
- Mattingly BA, Gotsick JE, Salamanca K. Latent sensitization to apomorphine following repeated low doses. *Behav Neurosci* 1988;102:553–8.
- Mattingly BA, Rowlett JK, Graff JT, Hatton BJ. Effects of selective D₁ and D₂ dopamine antagonists on the development of behavioral sensitization to apomorphine. *Psychopharmacology* 1991;105:501–7.
- Mattingly BA, Hart T, Lim K, Perkins C. Selective antagonism of dopamine D₁ and D₂ receptors does not block the development of behavioral sensitization to cocaine. *Psychopharmacology* 1994;114:239–42.
- Mattingly BA, Fields SE, Langfells MS, Rowlett JK, Robinet PM, Bardo MT. Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine. *Psychopharmacology* 1996;125:33–42.
- Nader MA, Mach RH. Self-administration of the dopamine D₃ agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. *Psychopharmacology* 1996;125:13–22.
- Parsons LH, Caine SB, Sokoloff P, Schwartz JC, Koob GF, Weiss F. Neurochemical evidence that postsynaptic nucleus accumbens D₃ receptor stimulation enhances cocaine reinforcement. *J Neurochem* 1996;67:1078–89.
- Pierre PJ, Vezina P. Predisposition to self-administer amphetamine: the contribution of response to novelty and prior exposure to the drug. *Psychopharmacology* 1997;129:277–84.
- Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animals models of amphetamine psychosis. *Brain Res Rev* 1986;11:157–98.
- Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of drug addiction. *Brain Res Rev* 1993;18:247–91.
- Rowlett JK, Mattingly BA, Bardo MT. Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats. *Neuropharmacology* 1991;30:191–7.
- Rowlett JK, Mattingly BA, Bardo MT. Locomotor activity and dopamine synthesis following 1 and 15 days of withdrawal from repeated apomorphine treatments. *Pharmacol Biochem Behav* 1997;57:13–8.
- Sanger DJ, Depoortere R, Perrault G. Discriminative stimulus effects of apomorphine and 7-OH-DPAT: a potential role for dopamine D₃ receptors. *Psychopharmacology* 1997;130:387–95.
- Shafer RA, Levant B. The D₃ dopamine receptor in cellular and organismal function. *Psychopharmacology* 1998;135:1–16.
- Shippenberg TS, Heidbreder C. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. *J Pharmacol Exp Ther* 1995;273:808–15.
- Staley JK, Mash DC. Adaptive increase in D₃ dopamine receptors in the brain reward circuits of human cocaine fatalities. *J Neurosci* 1996;16:6100–6.
- Stewart J, Badiani A. Tolerance and sensitization to the behavioral effects of drugs. *Behav Pharmacol* 1993;4:289–312.
- Svensson K, Carlsson A, Huff RM, Kling-Peterson T, Waters N. Behavioral and neurochemical data suggest functional differences between dopamine D₂ and D₃ receptors. *Eur J Pharmacol* 1994;263:235–43.
- Svensson K, Carlsson A, Waters N. Locomotor inhibition by D₃ ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. *J Neural Transm* 1994;95:71–4.
- Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. The dopamine D₃-receptor: a postsynaptic receptor inhibitory on locomotor activity. *J Neural Transm* 1993;94:11–9.
- Wolf ME, White FJ, Nasser R, Brooderson RJ, Khansa MR. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. *J Pharmacol Exp Ther* 1993;264:249–55.